Business

Arrhythmia’s quarterly loss widens

A plastinated human heart was displayed at a European cardiology conference.

Reuters/File 2013

A plastinated human heart was displayed at a European cardiology conference.

Arrhythmia Research Technology Inc.’s quarterly net loss widened to $2.89 million, or $1.06 per share, from $1.04 million, or 37 cents, in the same quarter last year. But the Fitchburg company’s total consolidated revenue from continuing operations grew 1.8 percent, to $4.88 million, from a year before. The company and its Micron Products subsidiary supply products for the medical and defense industries, including software to detect certain heart arrhythmias.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com